Abstract

 The sudden outbreak of highly contagious COVID 19 has challenged the existence of Homo sapiens. Although few repurposing old drugs are already used to prevent corona virus but presently, there is no specific promising treatment along with any vaccine for preventing COVID-19. The high infectivity of the causal pathogen SARS-CoV-2 virus combined with high mutation rates has been the greatest hurdle for the scientific societies to discover a potent vaccine or drug for cure which makes the situation even more alarming. Treatment unavailability of this fatal corona virus (COVID 19) has already caused more than 500,000 deaths and the curve is on the rise. Presently, there is no specific treatment for COVID-19 and the coming months will see the greatest public health challenge of this millennium. Development of safe and cheap treatment will prove to be a game changer in the race to move ahead of the curve. The conventional route of vaccine development though seems highly reproducible but not promising in terms of safety issues as the pathogen is highly infectious. In this aspect using Virus-like particles has been a promising vaccine development route for production of a low cost, safe, easy to manufacture and transportable vaccine to protect from novel corona virus (COVID-19). This review work would offer comprehensive fast hand information to medical practitioners and researchers dealing with COVID-19. A brief discussion has done about the ultra-structure of corona virus COVID-19, its systematic position and currently available treatments and their drawbacks. The prospects of vaccine development with their safety efficiency has elaborately discussed. A brief discussion has done on the safe route of vaccine development using Virus-like particles (VLPs) against worldwide COVID-19 pandemic.

Keywords: COVID-19; SARS-CoV-2; Corona Virus; Vaccine; Virus-like Particles

References

1. World Health Organization. Coronavirus. WHO (2020).
2. Gorbalenya AE., et al. “Severe acute respiratory syndrome-related coronavirus: The species and its viruses - A statement of the Coronavirus Study Group”. bioRxiv (2020).
3. World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19. WHO (2020).
4. WHO (World Health Organization).
5. https://scitechdaily.com/covid-19-world-map-372757-confirmed-cases-190-countries-16231-deaths/
6. Chan JF., et al. “Genomic characterization of the 2019 novel humanpathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan”. Emergency Microbes and Infections 9 (2020): 221-236.
7. World Health Organization. Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases: Interim guidance. Geneva: WHO (2020).
8. Mendoza SR., et al. “What Does Plant-Based Vaccine Technology Offer to the Fight against COVID-19?” Vaccines 8 (2020): 183.
9. Millet JK and Whittaker GR. “Host cell proteases: critical determinants of coronavirus tropism and pathogenesis”. Virus Research 202 (2015): 120-134.
10. Jia HP., et al. “ACE2 Receptor Expression and Severe Acute Respiratory Syndrome Coronavirus Infection Depend on Differentiation of Human Airway Epithelia”. Journal of Virology23 (2005): 14614-14621.
11. Corman VM., et al. “Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR”. Euro Surveilliance 25 (2020): i: 2000045.
12. David C Fajgenbaum., et al. “Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review”. Infectious Diseases and Therapy (2020).
13. https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/nearly-70-drugs-that-may-be-effective-against-covid 19identified/articleshow/74826381.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
14. Kotomina T., et al. “Recombinant live attenuated influenza vaccine viruses carrying CD8 T-cell epitopes of respiratory syncytial virus protect mice against both pathogens without inflammatory disease”. Antivirus Research 168 (2019): 9-17.
15. Wu T., et al. “Quantification of epitope abundance reveals the e_ect of direct and cross-presentation on influenza CTL responses”. Nature Communication 10 (2019): 2846.
16. Armbruster N., et al. “Advances in RNA vaccines for preventive indications: A case study of a vaccine against rabies”. Vaccines 7 (2019): 132.
17. CureVac Focuses on the Development of mRNA-based Coronavirus Vaccine to Protect People Worldwide.
18. Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) to Prevent SARS-CoV-2 Infection.
19. Safety and Immunity of Covid-19 aAPC Vaccine.

Citation

Citation: Moumita Gangopadhyay., et al. “Virus-like Particles (VLPs) based Vaccine Production: A Potentially Safe Candidate Vaccine against Worldwide COVID-19 Pandemic". Acta Scientific Clinical Case Reports 1.7 (2020): 08-13.

Copyright

Copyright: © 2020 Moumita Gangopadhyay., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.